CORE is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial of ~540 patients to evaluate the safety and efficacy of ISIS 678354, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with severe hypertriglyceridemia.
MAIN RESULTS:
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
N Engl J Med. 2026 Jan 29;394(5):429-441.
PRESENTATIONS
PUBLICATIONS
CORE on ClinicalTrials.gov
Contact Us about CORE